1. Home
  2. NRIX vs AVO Comparison

NRIX vs AVO Comparison

Compare NRIX & AVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRIX
  • AVO
  • Stock Information
  • Founded
  • NRIX 2009
  • AVO 1983
  • Country
  • NRIX United States
  • AVO United States
  • Employees
  • NRIX N/A
  • AVO N/A
  • Industry
  • NRIX Biotechnology: Pharmaceutical Preparations
  • AVO Farming/Seeds/Milling
  • Sector
  • NRIX Health Care
  • AVO Consumer Staples
  • Exchange
  • NRIX Nasdaq
  • AVO Nasdaq
  • Market Cap
  • NRIX 750.4M
  • AVO 827.7M
  • IPO Year
  • NRIX 2020
  • AVO 2020
  • Fundamental
  • Price
  • NRIX $12.94
  • AVO $11.52
  • Analyst Decision
  • NRIX Strong Buy
  • AVO Strong Buy
  • Analyst Count
  • NRIX 14
  • AVO 1
  • Target Price
  • NRIX $26.29
  • AVO $17.00
  • AVG Volume (30 Days)
  • NRIX 1.9M
  • AVO 268.0K
  • Earning Date
  • NRIX 10-09-2025
  • AVO 12-18-2025
  • Dividend Yield
  • NRIX N/A
  • AVO N/A
  • EPS Growth
  • NRIX N/A
  • AVO 66.53
  • EPS
  • NRIX N/A
  • AVO 0.55
  • Revenue
  • NRIX $83,687,000.00
  • AVO $1,426,600,000.00
  • Revenue This Year
  • NRIX $58.48
  • AVO $11.93
  • Revenue Next Year
  • NRIX N/A
  • AVO N/A
  • P/E Ratio
  • NRIX N/A
  • AVO $20.96
  • Revenue Growth
  • NRIX 48.32
  • AVO 25.34
  • 52 Week Low
  • NRIX $8.18
  • AVO $9.56
  • 52 Week High
  • NRIX $29.56
  • AVO $15.25
  • Technical
  • Relative Strength Index (RSI)
  • NRIX 70.14
  • AVO 41.12
  • Support Level
  • NRIX $11.37
  • AVO $11.15
  • Resistance Level
  • NRIX $13.24
  • AVO $11.72
  • Average True Range (ATR)
  • NRIX 0.83
  • AVO 0.25
  • MACD
  • NRIX 0.28
  • AVO -0.01
  • Stochastic Oscillator
  • NRIX 92.80
  • AVO 40.22

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About AVO Mission Produce Inc.

Mission Produce Inc is engaged in the business of producing and distributing avocados, serving retail, wholesale, and food service customers. Also, the company provides additional services like ripening, bagging, custom packing, and logistical management. The company's operating segments include Marketing and Distribution, International Farming and Blueberries. It generates maximum revenue from the Marketing and Distribution segment. The Marketing and Distribution segment sources fruit mainly from growers and then distributes fruit through a distribution network. Geographically distributed across North America, China, Europe, and the U.K.

Share on Social Networks: